WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2024 Issue has been successfully launched on NOVEMBER 2024.

Abstract

DEVELOPMENT AND EVALUATION OF A GENERIC ANTI - INFLAMMATORY DRUG FORMULATION

*Choubey Pravir, Manavalan R

ABSTRACT

Generic prototype formulation of an anti-inflammatory drug Celecoxib Capsules 400mg was developed and subjected to various evaluation studies such as physico-chemical properties in-process parameters during encapsulation, stability studies, comparative dissolution profile, and bioequivalence studies. The formulation and process parameters are established to be robust, stable and comparable to the reference product based on comparative in-vitro studies. Celecoxib Capsules 400mg formulation is suitable as a generic alternative to the reference drug product (Celebrex Capsules of Pfizer).

Keywords: Generic, Celecoxib Capsules Dissolution profile, Stability.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More